Syndax Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $68,481 | $45,871 | $37,958 | $20,042 |
Gross Profit | 70,053 | 39,493 | 36,679 | 19,157 |
EBITDA | -15,309 | -57,700 | -63,989 | -83,757 |
EBIT | -15,312 | -57,701 | -92,895 | |
Net Income | -68,014 | -60,715 | -71,847 | -84,846 |
Net Change In Cash | 68,481 | 45,871 | 37,958 | 20,042 |
Free Cash Flow | -69,544 | -70,666 | -87,795 | -95,162 |
Cash | 134,930 | 116,808 | 108,636 | 153,993 |
Basic Shares | 86,620 | 86,620 | 86,337 | 85,622 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $172,352 | $23,680 | $0 | $126,576 |
Gross Profit | 165,382 | 22,854 | -12 | -454 |
EBITDA | -251,637 | -313,821 | -209,140 | -151,724 |
EBIT | -251,643 | -313,829 | -209,152 | -151,757 |
Net Income | -285,422 | -318,758 | -209,360 | -143,749 |
Net Change In Cash | 172,352 | 23,680 | 0 | 126,576 |
Free Cash Flow | -323,167 | -274,903 | -160,601 | -133,900 |
Cash | 134,930 | 154,083 | 295,394 | 74,356 |
Basic Shares | 86,620 | 85,622 | 70,370 | 60,760 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.78 |
2025-09-30 | -$0.70 |
2025-06-30 | -$0.83 |
